Transcutaneous Electrical Acupoint Stimulation (TEAS) for Chronic Constipation
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Constipation - Functional
- Sponsor
- University of California, Los Angeles
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- spontaneous bowel movement (SBMs) per week
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
Transcutaneous electrical acupoint stimulation (TEAS) is an emerging technology for non-invasive neuromodulation that has broad potential implications and warrants further study. The investigators' clinical experience from the University of California, Los Angeles (UCLA) Center for East-West Medicine (CEWM) has also demonstrated that TEAS can be used as an effective self-care tool for patients with chronic illness who do not have the time or resources for frequent acupuncture treatments. Chronic constipation is the chosen area of study because of the large population with a substantial impairment in health-related quality of life and work productivity. The investigators have recently completed a randomized controlled trial (RCT) demonstrating the benefit of perineal self-acupressure on quality of life measurements in this population, which supports investigation into other acupuncture-based self-care interventions. Given these findings, the investigators hypothesize that home patient-administered TEAS can provide measurable improvements in both symptom severity and health related quality of life.
Detailed Description
This study will be a double blinded randomized controlled trial. Respondents will be screened by phone and qualified subjects will be sent home for 2 weeks to complete a bowel movement logbook, then return into the CEWM office where they will submit validated surveys (specifically, the PAC-SYM and PAC-QOL) and have a photo taken of their tongue. A baseline non-invasive heart rate variability (HRV) measurement will be taken at this time as well. Study personnel will instruct each subject on TEAS pad placement and how to use the device, but not tell the subjects where to place the pads. The subjects will been assigned to one of two experimental groups (verum and sham) based on a 1:1 random allocation, with the study personnel blinded to the allocation. Both groups will be given transcutaneous electrical nerve stimulator (TENS) units with pre-set parameters and access to the adjustable amplitude dial for self-adjustment of amplitude, with the verum group given pre-printed information on proper application on true acupoints, and sham group will be given information on non-acupuncture points. The subjects will be instructed on daily use for 30 minutes per day for at least 5 days per week, and asked to track device use as well as bowel movement frequency and quality using a logbook. They will also submit to an online survey every week during the 4-week trial period. At the conclusion of the study, they will return the units and repeat the survey and HRV measurements.
Investigators
Andrew Shubov, MD
Principal Investigator
University of California, Los Angeles
Eligibility Criteria
Inclusion Criteria
- •18 years of age or older
- •Satisfy a modified ROME-IV criteria for functional constipation including:
- •Fewer than three spontaneous bowel movements per week
- •and meet one of the following symptoms for at least 12 weeks in the preceding 12 months:
- •straining during \>25% of the bowel movements (BMs)
- •lumpy or hard stools during \>25% of BMs
- •sensation of incomplete evacuation during \>25% of BMs
- •sensation of anorectal obstruction or blockage for \>25% of BMs
- •manual maneuvers to facilitate \>25% of BMs
- •loose stools are rarely present without the use of laxatives
Exclusion Criteria
- •Pregnancy
- •Numbness around the genitals or groin, bladder or bowel dysfunction or incontinence, new sciatica type leg pain or new onset sexual dysfunction within the past year.
- •Any changes to constipation related medications over the past 1 month
- •Use of rescue medication (polyethylene glycol, bisacodyl, enema, etc) greater than once per week
- •Pacemaker, implanted cardiac defibrillator or other implanted electrical device
- •10% weight loss in past 6 months
- •New onset Hematochezia since last medical evaluation
Outcomes
Primary Outcomes
spontaneous bowel movement (SBMs) per week
Time Frame: 4 weeks
Comparison of weekly spontaneous bowel movement (SBMs) per week between the two groups using a paired t-test comparing the final time point to the lead-in measurement.
Secondary Outcomes
- PAC-QOL(4 weeks)
- PAC-SYM(4 weeks)
- Responder rate(4 weeks)
- HRV Changes(4 weeks)
- Bristol Stool Scale(4 weeks)